Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II sunitinib second-line trial in advanced or metastatic urothelial transitional cell carcinoma
2008-001004-22Phase 2Active
- Sponsor
- Centre René Huguenin
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in transitional cell carcinoma (TCC) and bladder cancer, sponsored by Centre René Huguenin. Primary endpoint: Objective tumor response rate. Started Mar 2008; status: active.
02
Drugs
sunitinib
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on 2008-001004-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001004-22.